// App-Quantinova.ai

: A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Researchers

Presenter

  • Omar Nadeem

Principal Investigators

  • Trevor J. Bayliss

  • Peter Barth

  • Jacob Laubach

  • Clifton C. Mo

  • Giada Bianchi

  • Kelly Masone

  • Kyle Griffin

  • Lindsay Issokson

  • Anna Barrell

  • Randi Doherty

  • Deborah Mailand

  • Alexandra Distaso

  • Sarah Patches

  • Kathryn Goodrich

  • Kathleen ONeill

  • Vaishali Sanchorawala

  • Leyla O. Shune

  • Paul G. Richardson

Medical Centers

  • Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

  • The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

  • Division of Hematologic Malignancies and Cellular Therapeutics (HMCT), University of Kansas Medical Center, Kansas City, KS

  • Amyloidosis Program, Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Boston, MA

  • Department of Data Science, Dana-Farber Cancer Institute, Boston, MA

  • Dana-Farber Cancer Institute, Boston, MA

  • Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Center for Multiple Myeloma Research, Harvard Medical School, Boston, MA

  • Department of Medicine, Alpert Medical School of Brown University, Providence, RI

  • Berkshire Health Services, Pittsfield, MA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Pomalidomide

  • CC-4047

  • Ixazomib

Outcome

  • N/A

Study Design

  • Safety

  • Open Label

  • Single Arm

  • Multicenteric

  • Dose Escalation

Phase

  • I/II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved